| Monday | ||||
Mersana Therapeutics… Mersana Therapeutics (MRSN) announced the appointment of Mohan Bala, Ph.D., as SVP, Strategic Product Planning & Program Leadership, effective Monday, October 25, 2021. Dr. Bala will assume strategic product planning responsibilities from Brian DeSchuytner who has been named SVP and CFO. Mr. DeSchuytner will continue to lead finance, business development, corporate strategy and investor relations and remain Mersana's principal financial officer. Mohan Bala, Ph.D., was most recently Chief Operating Officer at Constellation Pharmaceuticals (CNST). | ||||
| Over a week ago | ||||
SMid Cap Biotech Analyst… SMid Cap Biotech Analyst Fye holds a conference call with CEO Protopapas on October 20 at 11 am hosted by JPMorgan. | ||||
SMid Cap Biotech Analyst… SMid Cap Biotech Analyst Fye holds a conference call with CEO Protopapas on October 20 at 11 am hosted by JPMorgan. | ||||
SMid Cap Biotech Analyst… SMid Cap Biotech Analyst Fye holds a conference call with CEO Protopapas on October 20 at 11 am hosted by JPMorgan. | ||||
BTIG analyst Kaveri… BTIG analyst Kaveri Pohlman assumed coverage of Mersana Therapeutics with a Buy rating and $32 price target. The analyst assumed coverage of 12 Immuno-oncology companies. Pohlman believes "much of the most promising work" involves broader immune involvement in the anti-tumor battle either involving or in combination with less-systemically toxic therapeutic cytokines. The world of allogeneic cellular therapies is "very close to catching the autologous world but that these approaches will always be complex for smaller hospitals to employ leaving this approach for a subset of patients," Pohlman tells investors in a research note. | ||||
Wedbush Biotechnology… Wedbush Biotechnology Analyst Nierengarten holds a conference call with President & CEO Protopapas and SVP DeSchuuytner on October 11 at 1 pm hosted by Wedbush. | |
Wedbush Biotechnology… Wedbush Biotechnology Analyst Nierengarten holds a conference call with President & CEO Protopapas and SVP DeSchuuytner on October 11 at 1 pm hosted by Wedbush. | |
Wedbush Biotechnology… Wedbush Biotechnology Analyst Nierengarten holds a conference call with President & CEO Protopapas and SVP DeSchuuytner on October 11 at 1 pm hosted by Wedbush. | |
Mersana Therapeutics… Mersana Therapeutics announced that XMT-2056, its first Immunosynthen STING-agonist ADC candidate, targets a novel epitope of human epidermal growth factor receptor 2, or HER2, and presented new preclinical data during a plenary session at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics. New preclinical data presented at the Triple Meeting include: XMT-2056 demonstrated increased efficacy in both high and low HER2 SCID mouse models in comparison to benchmark agents such as a trastuzumab-TLR7/8 agonist ADC as well as a small molecule systemically-administered STING agonist. XMT-2056 showed excellent in vivo efficacy as a single agent in a SKOV3 HER2 high model and this efficacy is further enhanced by combining XMT-2056 with a 3 mg/kg dose of trastuzumab. XMT-2056 was generally well-tolerated in NHP studies with no clinical signs and no adverse findings in clinical pathology or histopathology after single and repeat IV doses of 9 mg/kg, at exposures far exceeding those necessary for efficacy in mouse models, indicating the potential for a wide therapeutic index. | |
Mersana Therapeutics… Mersana Therapeutics announced that it will disclose the target and present new preclinical data for XMT-2056, its first Immunosynthen STING-agonist ADC candidate, in a plenary session at the upcoming AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics. |